Company BeyondSpring Inc.

Equities

BYSI

KYG108301006

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
2.44 ^USD	+2.09%		-7.22%	+171.11%

May. 21	Top Premarket Decliners	MT
May. 15	Transcript : BeyondSpring Inc. - Special Call

BeyondSpring Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. The Company operates through two segments: the Plinabulin pipeline and Targeted Protein Degradation (TPD) platform. Plinabulin is being developed as a pipeline in a drug in various cancer indications as a direct anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). Plinabulin is a small molecule derived from a natural compound found in marine microorganisms. It is a selective immunomodulating microtubule-binding agent (SIMBA), which may provide multiple therapeutic opportunities. The TPD platform is utilizing molecular glue technology to develop therapeutic agents and discover and develop new chemical entities for the debilitating diseases and disorders. The Company is also developing three small-molecule immune agents.

Number of employees: 36

USD in Million	2022	Weight	2023	Weight	Delta
Targeted Protein Degradation Platform 100.0 %	1	100.0 %	2	100.0 %	+29.61%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	1	100.0 %	2	100.0 %	+29.61%

Managers	Title	Age	Since
Lan Huang CEO	Chief Executive Officer	53	12-12-31

Members of the board	Title	Age	Since
Patrick Fabbio BRD	Director/Board Member	56	18-01-01
Lan Huang CEO	Chief Executive Officer	53	12-12-31
Matthew Kirkby BRD	Director/Board Member	55	16-10-12
Brendan Delaney BRD	Director/Board Member	49	21-07-13
Jiang Wen Majeti BRD	Director/Board Member	56	22-07-31
Si Hai Xu BRD	Director/Board Member	52	22-07-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	39,029,163	28,736,737 ( 73.63 %)	0	73.63 %

Name	Equities	%	Valuation
Lan Huang 26.17 %	10,210,523	26.17 %	23 M $
Decheng Capital LLC 12.71 %	4,958,143	12.71 %	11 M $
Fidelity Management & Research Co. LLC 1.146 %	447,163	1.146 %	1 M $
BlackRock Institutional Trust Co. NA 0.5191 %	202,544	0.5191 %	459 775 $
Jiang Wen Majeti 0.1305 %	50,914	0.1305 %	115 575 $
Capstone Capital LLC 0.1294 %	50,500	0.1294 %	114 635 $
STATE STREET CORPORATION 0.0825 %	32,200	0.0825 %	73 094 $
Y-Intercept (Hong Kong) Ltd. 0.0786 %	30,677	0.0786 %	69 637 $
Tanaka Capital Management, Inc. 0.0755 %	29,473	0.0755 %	66 904 $
Patrick Fabbio 0.0630 %	24,592	0.0630 %	55 824 $

BeyondSpring, Inc.

100 Campus Drive 4th floor, Suite 410

07932, Florham Park

http://www.beyondspringpharma.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
BEYONDSPRING INC.	+171.11%	95.23M
VERTEX PHARMACEUTICALS INCORPORATED	+18.72%	125B
REGENERON PHARMACEUTICALS, INC.	+14.19%	108B
BIONTECH SE	-4.93%	24.21B
ARGENX SE	+3.23%	22.78B
GENMAB A/S	-10.44%	17.96B
WUXI APPTEC CO., LTD.	-41.74%	16.43B
BEIGENE, LTD.	-13.31%	16.37B
NEUROCRINE BIOSCIENCES, INC.	+2.44%	13.58B
SAREPTA THERAPEUTICS, INC.	+27.89%	11.66B

Bio Therapeutic Drugs